Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00037791 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
NCT00037791 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 180 participants.
The verdict
NCT00037791, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
Study Summary
Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has demonstrated the ability to increase platelet counts. This study will test the safety and efficacy of this investigational drug in the prevention of thrombocytopenia in patients with solid tumors, lymphomas or multiple myeloma who are receiving myelosuppressive treatment regimens requiring platelet transfusion support.
Interventions
- DRUG (PN-152,243)/PN-196,444
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 1999-12 |
| Est. Completion | 2002-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00037791
The ClinicalTrials.gov registry entry for NCT00037791 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which (PN-152,243)/PN-196,444 is the first listed.
NCT00037791 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00037791 about?
NCT00037791 is a clinical study titled "Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia". Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has demonstrated the ability to increase platelet counts. This study will test the safety and efficacy of this investigational drug in t...
What is the current status of trial NCT00037791?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 1999-12. Estimated completion is 2002-09.
What interventions are being tested in trial NCT00037791?
The interventions under investigation include: (PN-152,243)/PN-196,444 (DRUG).
Who is sponsoring clinical trial NCT00037791?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.